The estimated Net Worth of John F Mauldin is at least $201 mil dollars as of 2 January 2014. John Mauldin owns over 618 units of AgeX Therapeutics Inc stock worth over $200,621 and over the last 13 years John sold AGE stock worth over $0.
John has made over 10 trades of the AgeX Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently John bought 618 units of AGE stock worth $4,950 on 2 January 2014.
The largest trade John's ever made was buying 4,947 units of AgeX Therapeutics Inc stock on 24 April 2012 worth over $14,693. On average, John trades about 735 units every 41 days since 2012. As of 2 January 2014 John still owns at least 18,074 units of AgeX Therapeutics Inc stock.
You can see the complete history of John Mauldin stock trades at the bottom of the page.
John's mailing address filed with the SEC is 2900 MCKINNON, #1708, , DALLAS, TX, 75201.
Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West, eJudith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
AgeX Therapeutics Inc executives and other stock owners filed with the SEC include: